Last reviewed · How we verify
Ogen .625 (estrone sulphate)
Ogen .625 (generic name: estrone sulphate) is a estropipate drug developed by Pfizer. It is currently FDA-approved (first approved 1977) for Atrophic vaginitis, Female hypogonadism syndrome.
At a glance
| Generic name | estrone sulphate |
|---|---|
| Sponsor | Pfizer |
| Drug class | estropipate |
| Target | Steryl-sulfatase |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Atrophic vaginitis
- Female hypogonadism syndrome
Common side effects
Drug interactions
- atazanavir
- darunavir
- fosamprenavir
- fosphenytoin
- lamotrigine
- letrozole
- nelfinavir
- phenobarbital
- phenytoin
- saquinavir
- tipranavir
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction (PHASE4)
- Pharmacokinetic Effect of Evotaz/Microgynon Co-administration (PHASE1)
- Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri (EARLY_PHASE1)
- Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women (PHASE2)
- High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy (PHASE2)
- Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females (PHASE1)
- Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ogen .625 CI brief — competitive landscape report
- Ogen .625 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Ogen .625
What is Ogen .625?
Ogen .625 (estrone sulphate) is a estropipate drug developed by Pfizer, indicated for Atrophic vaginitis, Female hypogonadism syndrome.
What is Ogen .625 used for?
Ogen .625 is indicated for Atrophic vaginitis, Female hypogonadism syndrome.
Who makes Ogen .625?
Ogen .625 is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of Ogen .625?
estrone sulphate is the generic (nonproprietary) name of Ogen .625.
What drug class is Ogen .625 in?
Ogen .625 belongs to the estropipate class. See all estropipate drugs at /class/estropipate.
When was Ogen .625 approved?
Ogen .625 was first approved on 1977.
What development phase is Ogen .625 in?
Ogen .625 is FDA-approved (marketed).
What does Ogen .625 target?
Ogen .625 targets Steryl-sulfatase and is a estropipate.
Related
- Drug class: All estropipate drugs
- Target: All drugs targeting Steryl-sulfatase
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Atrophic vaginitis
- Indication: Drugs for Female hypogonadism syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing